medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-3-75-79medsovet-1754Research ArticleДРУГИЕ ПРОБЛЕМЫ ЭНДОКРИНОЛОГИИOTHER PROBLEMS OF ENDOCRINOLOGYСОВРЕМЕННЫЙ ВЗГЛЯД НА ЛЕЧЕНИЕ АКРОМЕГАЛИИ АНАЛОГАМИ СОМАТОСТАТИНАCURRENT VIEWS ON THE TREATMENT OF ACROMEGALY WITH SOMATOSTATIN ANALOGUESИловайскаяИ. А.IlovaiskayaI. A.

к.м.н.

PhD in Medicine

Московский областной научно-исследовательский клинический институт им. М.Ф. ВладимирскогоРоссияMoscow Regional Research and Clinical Institute named after M.F. VladimirskiyRussian Federation201730122017037579Copyright © Иловайская И.А., 20172017Иловайская И.А.Ilovaiskaya I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1754

Акромегалия является заболеванием с полиорганным поражением. Кроме того, при акромегалии часто встречаются психологические расстройства и отмечается значительное снижение качества жизни. Нейрохирургическое лечение (транссфеноидальная аденомэктомия) рекомендуется в качестве первой линии лечения у большинства пациентов с акромегалией. Согласно современным рекомендациям больным, не достигшим биохимического контроля после оперативного лечения, обязательно назначается медикаментозная терапия [1, 2, 6]. Если радикальное удаление соматотропиномы маловероятно (т.е. опухоль с распространением за пределы турецкого седла, инвазивная, размерами 20 мм и более) и нет строгих показаний для операции, многие международные эксперты в качестве первой линии лечения рекомендуют применять аналоги соматостатина, которые являются безусловными лидерами среди препаратов для терапии акромегалии.

Acromegaly is a disease with multiple organ failure. Furthermore, acromegaly is frequently accompanied by psychological disorders, with a significant decrease in the quality of life. Neurosurgical treatment (transsphenoidal adenomectomy) is recommended as first-line treatment for most patients with acromegaly. According to the recent guidelines, patients after surgery who failed to achieve biochemical control should receive pharmacotherapy. [1, 2, 6] If radical removal of somatotropinoma is unlikely (for an invasive tumor that spread outside the sella, 20 mm or more in size) and there are no strict indications for surgery, many global experts recommend somatostatin analogues as the first-line treatment, which are the absolute leaders among drugs for the treatment of acromegaly.

акромегалиямедикаментозная терапияаналоги соматостатиналанреотид Аутожельacromegalypharmacotherapysomatostatin analogueslanreotide AutogelReferencesАкромегалия: патогенез, клиника, диагностика, дифференциальная диагностика, методы лечения (Пособие для врачей). Под ред. Дедова И.И., Мельниченко Г.А. М.: «УП Принт» 2012. 79 с.Акромегалия: патогенез, клиника, диагностика, дифференциальная диагностика, методы лечения (Пособие для врачей). Под ред. Дедова И.И., Мельниченко Г.А. М.: «УП Принт» 2012. 79 с.Katznelson L, Laws ER, Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab., 2014, 99: 3933–3951.Katznelson L, Laws ER, Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab., 2014, 99: 3933–3951.Pantanetti P, Sonino N, Arnaldi G, Boscaro M. Self image and quality of life in acromegaly. Pituitary, 2002, 5: 17–19.Pantanetti P, Sonino N, Arnaldi G, Boscaro M. Self image and quality of life in acromegaly. Pituitary, 2002, 5: 17–19.Webb SM, Badia X, Surinach NL, Spanish AcroQol Study Group Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol., 2006, 155: 269–277.Webb SM, Badia X, Surinach NL, Spanish AcroQol Study Group Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol., 2006, 155: 269–277.Webb SM, Badia X. Quality of Life in Acro megaly. Neuroendocrinology, 2016, 103(1): 106-11.Webb SM, Badia X. Quality of Life in Acro megaly. Neuroendocrinology, 2016, 103(1): 106-11.Melmed S, Colao A, Barkan A, et al. Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab, 2009 May, 94(5): 1509-17.Melmed S, Colao A, Barkan A, et al. Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab, 2009 May, 94(5): 1509-17.Giustina A, Chanson P, Bronstein MD, et al. Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab, 2010 Jul, 95(7): 3141-3148.Giustina A, Chanson P, Bronstein MD, et al. Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab, 2010 Jul, 95(7): 3141-3148.Ritvonen E, Löyttyniemi E, Jaatinen P. Mortality in acromegaly: a 20-year follow-up study. Endocr Relat Cancer, 2015 Jun, 23(6): 469-80.Ritvonen E, Löyttyniemi E, Jaatinen P. Mortality in acromegaly: a 20-year follow-up study. Endocr Relat Cancer, 2015 Jun, 23(6): 469-80.Ramos-Leví AM, Marazuela M. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. Endocrine, 2017 Feb, 55(2): 346-359.Ramos-Leví AM, Marazuela M. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. Endocrine, 2017 Feb, 55(2): 346-359.Jane J.A. Jr., Starke R.M., Elzoghby М.А., Reames D.L., et al. Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome. J Clin Endocrinol Metab, 2011, 96 (9): 2732-40.Jane J.A. Jr., Starke R.M., Elzoghby М.А., Reames D.L., et al. Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome. J Clin Endocrinol Metab, 2011, 96 (9): 2732-40.Shin SS, Tormenti MJ, Paluzzi A, et al. Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission. Pituitary, 2013 Dec, 16(4): 435-44.Shin SS, Tormenti MJ, Paluzzi A, et al. Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission. Pituitary, 2013 Dec, 16(4): 435-44.Cola, A, Auriemma RS, Galdiero M, Lombardi G. & Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. Clin Endocrinol Metab, 2009, 94: 3746–3756.Cola, A, Auriemma RS, Galdiero M, Lombardi G. & Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. Clin Endocrinol Metab, 2009, 94: 3746–3756.Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab, 2008, 93: 2957–2968.Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab, 2008, 93: 2957–2968.Bevan JS, Newell-Price J, Wass JA, et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf), 2008 Mar, 68(3): 343-349.Bevan JS, Newell-Price J, Wass JA, et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf), 2008 Mar, 68(3): 343-349.Salvatori R et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary, 2010, 13: 115–122.Salvatori R et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary, 2010, 13: 115–122.Witek P, Mucha S, Ruchała M. Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly. Endokrynol Pol, 2016, 67(6): 572-579.Witek P, Mucha S, Ruchała M. Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly. Endokrynol Pol, 2016, 67(6): 572-579.Melmed S, Cook D, Schopohl J, et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary, 2010, 13(1): 18-28.Melmed S, Cook D, Schopohl J, et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary, 2010, 13(1): 18-28.Burness CB, Dhillon S, Keam SJ. Lanreotide autogel(®: a review of its use in the treatment of patients with acromegaly. Drugs, 2014 Sep, 74(14): 1673-91.Burness CB, Dhillon S, Keam SJ. Lanreotide autogel(®: a review of its use in the treatment of patients with acromegaly. Drugs, 2014 Sep, 74(14): 1673-91.Ronchi CL, Boschetti M, Degli Uberti EC et al. Italian Multicenter Autogel Study Group in Acromegaly. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf), 2007 Oct, 67(4): 512-9.Ronchi CL, Boschetti M, Degli Uberti EC et al. Italian Multicenter Autogel Study Group in Acromegaly. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf), 2007 Oct, 67(4): 512-9.Kimmell KT, Weil RJ, Marko NF. Multi-modal management of acromegaly: a value perspective. Pituitary, 2015 Oct, 18(5): 658-65.Kimmell KT, Weil RJ, Marko NF. Multi-modal management of acromegaly: a value perspective. Pituitary, 2015 Oct, 18(5): 658-65.Colao A, Auriemma RS, Rebora A, et al. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf), 2009, 71(2): 237-245.Colao A, Auriemma RS, Rebora A, et al. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf), 2009, 71(2): 237-245.Caron PJ, Bevan JS, Petersenn S, et al. PRIMARYS Investigators. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab, 2014 Apr, 99(4): 1282-90.Caron PJ, Bevan JS, Petersenn S, et al. PRIMARYS Investigators. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab, 2014 Apr, 99(4): 1282-90.Caron PJ, Bevan JS, Petersenn S et al. PRIMARYS Investigators Group. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary, 2016 Apr, 19(2): 149-57.Caron PJ, Bevan JS, Petersenn S et al. PRIMARYS Investigators Group. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary, 2016 Apr, 19(2): 149-57.Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and metaanalysis. PLoS One, 2013 Apr 25, 8(4): e61523.Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and metaanalysis. PLoS One, 2013 Apr 25, 8(4): e61523.Polanco-Briceno S, Glass D, Plunkett C. Commu nication practices and awareness of resources for acromegaly patients among endocrinologists. Patient Prefer Adherence, 2016 Dec 14, 10: 2531-2541.Polanco-Briceno S, Glass D, Plunkett C. Commu nication practices and awareness of resources for acromegaly patients among endocrinologists. Patient Prefer Adherence, 2016 Dec 14, 10: 2531-2541.

The authors declare that there are no conflicts of interest present.